| 2.63 -0.61 (-18.83%) | 03-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 4.09  |
1-year : | 5.13 |
| Resists | First : | 3.5 |
Second : | 4.4 |
| Pivot price | 2.51 |
|||
| Supports | First : | 2.04 |
Second : | 1.7 |
| MAs | MA(5) : | 2.92 |
MA(20) : | 2.5 |
| MA(100) : | 7.07 |
MA(250) : | 8.69 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 59.4 |
D(3) : | 52.1 |
| RSI | RSI(14): 48.6 |
|||
| 52-week | High : | 46.5 | Low : | 2.04 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CODX ] has closed below upper band by 42.0%. Bollinger Bands are 66.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 28 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.16 - 3.18 | 3.18 - 3.2 |
| Low: | 2.66 - 2.68 | 2.68 - 2.7 |
| Close: | 2.67 - 2.7 | 2.7 - 2.73 |
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
Thu, 12 Mar 2026
Japan patent backs Co-Diagnostics' compact PCR device for rapid infection tests - Stock Titan
Thu, 12 Mar 2026
Co-Diagnostics Receives Japanese Patent Covering Co-Dx PCR Platform Technologies - PR Newswire
Tue, 10 Mar 2026
Co-Diagnostics Regains Compliance with Nasdaq Listing Requirements - Yahoo Finance UK
Mon, 09 Feb 2026
Co-Diagnostics to Showcase PCR Platform at World Health Expo Labs Dubai - PR Newswire
Tue, 30 Dec 2025
Co-Diagnostics Announces Reverse Stock Split - PR Newswire
Thu, 13 Nov 2025
Co-Diagnostics Reports Third Quarter 2025 Financial Results - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 1.94e+006 (%) |
| Held by Institutions | 5.7 (%) |
| Shares Short | 38 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.433e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 824.4 % |
| Return on Equity (ttm) | -38 % |
| Qtrly Rev. Growth | 507890 % |
| Gross Profit (p.s.) | -55.22 |
| Sales Per Share | -44.38 |
| EBITDA (p.s.) | 123457 |
| Qtrly Earnings Growth | -29.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.07 |
| Price to Cash Flow | 0.15 |
| Dividend | 0 |
| Forward Dividend | 75070 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|